BioSpace News Archive

Cannmart Inc. (“Cannmart” or “Cannmart.com”) has received its Access to Cannabis for Medical Purposes Regulations (“ACMPR”) medical cannabis “sales-only” license with no cultivation (the “Sales License”), which is the first of its kind to be issued by Health Canada.

Alzheimer’s Research UK, is calling on the UK government to adopt a bold new action plan to bring about a life-changing dementia treatment and improve the lives of people with the condition.

Alzheimer’s Research UK, one of the top dementia research funders in the world, is calling on the UK government to adopt a bold new action plan to bring about a life-changing dementia treatment and improve the lives of people with the condition.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer.

Evofem Biosciences Inc., (NASDAQ: EVFM) (“Evofem” or the “Company”), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, today announced detailed results of its commissioned Consumer Survey conducted by The Harris Poll

Seniorlink, Inc., a leading tech-enabled health services company, named Julie Carita as the new District Manager for Boston for the company’s subsidiary, Caregiver Homes.

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present an overview of its pipeline at IDWeek 2018, October 3-7, 2018 in San Francisco.

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform today announced that it will present a poster entitled, “The Use of Self-delivering RNAi to Enhance NK Cell Cytotoxicity,” at the 16th Annual Discovery on Target Conference.

fter 100 days of action, DHHS Secretary Alex M. Azar released a report on the early results of the American Patient First Blueprint. The report reiterates the Administration’s call for greater competition in the pharmaceutical marketplace to address rising drug prices and reduce out-of-pocket costs.

5-year Growth Includes a New, Yet Historic Corporate Home and a Renewed Passion for Ending Preventable Blindness